Literature DB >> 3764522

Mezlocillin prophylaxis against infection after cesarean section: a comparison of techniques.

J P Lavery, K C Huang, W L Koontz, J Reinstine, C Marcell, N Rosenberg.   

Abstract

We studied 212 patients undergoing emergency cesarean section at an urban hospital. Four techniques of antibiotic prophylaxis were used, including single-dose and triple-dose parenteral therapy, parenteral and lavage therapy, and lavage therapy alone. One agent, mezlocillin, was used for all patients. There was no significant difference in surgically related infectious morbidity among the groups. This antibiotic proved efficacious when related to historical controls, and was the most economical of the modalities of administration studied.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3764522     DOI: 10.1097/00007611-198610000-00013

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Intracavity lavage and wound irrigation for prevention of surgical site infection.

Authors:  Gill Norman; Ross A Atkinson; Tanya A Smith; Ceri Rowlands; Amber D Rithalia; Emma J Crosbie; Jo C Dumville
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

Review 2.  Different classes of antibiotics given to women routinely for preventing infection at caesarean section.

Authors:  Gillian M I Gyte; Lixia Dou; Juan C Vazquez
Journal:  Cochrane Database Syst Rev       Date:  2014-11-17

3.  Different classes of antibiotics given to women routinely for preventing infection at caesarean section.

Authors:  Myfanwy J Williams; Carolina Carvalho Ribeiro do Valle; Gillian Ml Gyte
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

Review 4.  Different regimens of penicillin antibiotics given to women routinely for preventing infection after cesarean section: A systematic review and meta analysis.

Authors:  Dan Liu; Lingli Zhang; Chuan Zhang; Min Chen; Li Zhang; Jinke Li; Guanjian Liu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.